Shares of Apellis Pharmaceuticals (NASDAQ: APLS) surged in morning trading on Monday after a Bloomberg report that larger pharma companies could be interested in the biotech firm focused on rare diseases and ophthalmology.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The report stated that Apellis is speaking to advisors regarding its options following the takeover interest. Bloomberg added that the company ”may also consider seeking partnerships or licensing agreements for some of its ophthalmology products.”
The deliberations are ongoing and the company currently prefers to stay independent.
Analysts rate APLS stock a Strong Buy based on nine Buys and two Holds.
